KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBIT Margin (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBIT Margin for 16 consecutive years, with 5.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 2670.0% year-over-year to 5.1%, compared with a TTM value of 12.71% through Dec 2025, down 425.0%, and an annual FY2025 reading of 12.71%, down 425.0% over the prior year.
  • EBIT Margin was 5.1% for Q4 2025 at Biomarin Pharmaceutical, up from 6.02% in the prior quarter.
  • Across five years, EBIT Margin topped out at 33.55% in Q2 2025 and bottomed at 14.65% in Q4 2021.
  • Average EBIT Margin over 5 years is 8.19%, with a median of 6.91% recorded in 2022.
  • The sharpest move saw EBIT Margin soared 2128bps in 2022, then plummeted -2670bps in 2025.
  • Year by year, EBIT Margin stood at 14.65% in 2021, then surged by 83bps to 2.43% in 2022, then surged by 366bps to 6.48% in 2023, then soared by 233bps to 21.6% in 2024, then tumbled by -124bps to 5.1% in 2025.
  • Business Quant data shows EBIT Margin for BMRN at 5.1% in Q4 2025, 6.02% in Q3 2025, and 33.55% in Q2 2025.